Relay Therapeutics

RLAY Rare disease Lead: NDA Submitted 1 Biotech Distilled article ↓

Most recent annual filing: 2026-02-26

Catalyst timeline

Zovegalisib 1L combo filingBy YE2026Zovegalisib 1L combo filing, By YE2026, material
Zovegalisib ReInspire readoutBy YE2026Zovegalisib ReInspire readout, By YE2026, material
Zovegalisib ReDiscover-2 enrollment doneBy YE2026Zovegalisib ReDiscover-2 enrollment done, By YE2026, notable
Zovegalisib + atirmociclib triplet 1L-supportive1H 2027Zovegalisib + atirmociclib triplet 1L-supportive, 1H 2027, notable
Zovegalisib + atirmociclib AI Ph3Early 2027Zovegalisib + atirmociclib AI Ph3, Early 2027, routine
DESRES exclusivity window corporate updateAug 2027DESRES exclusivity window corporate update, Aug 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (5 active programs)

zovegalisib

RLY-2608

Small Molecule Target: PI3Kα, PIK3CA

Breast Cancer Phase 3 Phase 1/2 trial oral Pfizer NCT05216432
PIK3CA-Related Overgrowth Spectrum Phase 2 Phase 1/2 trial oral NCT06789913
Vascular Anomalies Phase 2 Phase 1/2 trial

RLY-8161

Small Molecule Target: NRAS

Melanoma Phase 1 NCT07584226

lirafugratinib

RLY-4008

Small Molecule Target: FGFR2

Cholangiocarcinoma NDA Submitted oral Elevar Therapeutics

Technology platforms

Dynamo

Integrates leading-edge computational and experimental approaches — including cryo-EM structural biology and long time-scale molecular dynamic simulations — to drug protein targets that have previously been intractable or inadequately addressed; enabled discovery of allosteric, pan-mutant, isoform-selective PI3Kα inhibitors; focus areas include oncology and genetic disease

Targets: PI3Kα, PIK3CA

Dynamo · D. E. Shaw Research

Motion-Based Drug Design platform integrating computational and experimental approaches (cryo-EM, molecular dynamics simulations, machine learning) to discover small molecule drugs against dynamic protein targets; focus areas: precision oncology and genetic diseases

Discontinued (1)

migoprotafib — undisclosed · Genentech terminated the Genentech Agreement without cause; we will not continue development of migoprotafib

Biotech Distilled coverage (1)

2026-08-10 Relay Therapeutics (RLAY) — Scientific Deep Dive for Zovegalisib and Pipeline Products 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.